IDM Pharma, Inc. Receives Special Protocol Assessment From FDA For Phase 2/3 Trial Of Bexidem For Superficial Bladder Cancer

IRVINE, Calif.--(BUSINESS WIRE)--June 13, 2006--IDM Pharma Inc. (NASDAQ: IDMI - News) announced today that it has received a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration (FDA) for the planned Phase 2/3 clinical trial in the U.S. of Bexidem for the treatment of superficial bladder cancer. The SPA is a process that allows for official FDA evaluation of a Phase 3 clinical trial and provides the trial sponsor with binding written agreement that the design and analysis of the study are adequate to support a license application submission if the study is performed according to the SPA. For more information about the SPA process, please visit the FDA website: www.fda.gov/cber/gdlns/protocol.pdf.